Almost half a billion people worldwide suffer from lung or heart diseases. While the prevalence of such diseases, especially chronic ones, is rapidly growing, the methods of the initial examination – with a stethoscope – have barely changed. Inadequately carried out examination or drawbacks of subjective interpretations lead to unnecessary referrals to more advanced and costly tests, delayed diagnose or increased severity of the condition, leading to poorer treatment, rising hospitalization times and related cost, and most importantly, having detrimental effect on person’s health. Newly developed “digital” solutions, even those trying to move into AI area, have added new device features which either compromise the user experience and workflows, have little added clinical value, or both. Medsensio has developed a cloud-based platform for automatic detection of abnormal breathing using deep learning. The company is specializing in AI algorithms for breathing analysis using world's largest annotated dataset of lung sounds and is planning a Horizon 2020 collaboration with 2 potential partners with complementary backgrounds across the value chain: one in medical device development at TRL 7 who aims to integrate with Medsensio platform, and another with network of marketing and sales channels to reach the market. Horizon2020 project would support achieving maturity of the combined solution with an end-to-end integration, clinically and economically validating its value at pre-commercial KOL-level for successful market introduction and full commercialization. Combining industry-leading expertise and innovative technologies with a broad network and distribution capacities the potential partners will ensure quick market take up to capture the opportunity which relates to a billion-euro market.
Project leader: Anna Dranovska
Institution: MEDSENSIO AS